Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Sentiment:

SEC Form 4 Filing


Mary Lynne Hedley, a director at Eli Lilly, acquired 16 shares of common stock through a deferral plan, while also holding 1,437 shares directly and 98 shares indirectly through a trust.

Summary

  • Mary Lynne Hedley, a director at Eli Lilly & Co, has reported a transaction involving the company's common stock.
  • On January 16, 2024, Ms. Hedley acquired 16 shares of common stock at a price of $634.57 per share.
  • These shares were acquired through the Lilly Directors' Deferral Plan, where they are deferred in lieu of cash compensation and will be settled in shares after her separation from service.
  • Following this transaction, Ms. Hedley directly owns 1,437 shares and indirectly owns 98 shares through a trust.
  • Ms. Hedley disclaims beneficial ownership of the reported securities held in trust except to the extent of her pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director's participation in a stock deferral plan, which is a normal occurrence and can be seen as a sign of confidence in the company.

Positives

  • The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It reflects a director's participation in a company stock deferral plan.

Comparison to Industry Standards

  • Director stock acquisitions are a common practice in publicly traded companies, often as part of compensation or incentive plans.
  • Deferral plans are also a standard method for directors to receive equity compensation, aligning their interests with long-term shareholder value.
  • The specific details of the Lilly Directors' Deferral Plan would need to be compared to similar plans at other pharmaceutical companies to assess its competitiveness.

Stakeholder Impact

  • The transaction has a minor positive impact on shareholders as it indicates a director's continued investment in the company.

Key Dates

DateDescription
01/16/2024Date of the stock acquisition transaction.
01/17/2024Date the form was signed.

Keywords

Eli Lilly, Director, Share Acquisition, Stock Deferral Plan, Beneficial Ownership, Common Stock, Lilly Directors' Deferral Plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.